Cite
HARVARD Citation
Link, J. et al. (2019). Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®. Bioorganic & medicinal chemistry letters. 29 (16), pp. 2415-2427. [Online].